OrthoPediatrics price target lowered to $51 from $57 at Truist

Truist analyst Samuel Brodovsky lowered the firm’s price target on OrthoPediatrics to $51 from $57 but keeps a Buy rating on the shares. The company’s Q2 results were “solid” and there’s is room for upside from the unchanged guidance, the analyst tells investors in a research note. The stock is at an attractive entry point into what the firm sees as a 20% grower at a time when expectations are low, Truist added.